3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Hematologic Neoplasms
1
Febrile Neutropenia
1
Interventions
fludarabine
6
Cyclophosphamide
5
fludarabine phosphate
4
Whole-Body Irradiation
4
itacitinib
3
angiotensin I (1-7)
3
pembrolizumab
2
Tacrolimus
2
Olanzapine
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
INCB039110
2
CTLA-4 Antigen
2
Busulfan
2
Brentuximab Vedotin
2
Bendamustine Hydrochloride
2
AP 1903 reagent
2
tazemetostat
1
tafasitamab
1
ruxolitinib
1
pomalidomide
1
ofatumumab
1
merphos
1
lopinavir-ritonavir drug combination
1
ivosidenib
1
ibrutinib
1
fedratinib
1
enasidenib
1
daratumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Hematologic Neoplasms
×
ceftolozane, tazobactam drug combination
×
Clear all
NCT05061654
2023-08-14
CEF-10
Hamad Medical Corporation
Phase 4
Withdrawn